ME. How much information do medical practitioners and endocrinologists have about diabetic retinopathy? Clinics. 2007;62(3):273-8.
OBJECTIVE:The objective of this study was to use a questionnaire to evaluate knowledge concerning diabetic retinopathy among the physicians present at the 12th Latin American Congress on Diabetes held in São Paulo, Brazil, September 2004. METHODS: A questionnaire about their experience and management of patients with diabetes mellitus and the ophthalmologic examination was administered to 168 endocrinologists attending the meeting. RESULTS: Among the 168 physicians, only 36.9% correctly referred patients with diabetes type 1 to an ophthalmologist, whereas 86.9% referred patients with the type 2 disorder as recommended by the American Academy of Ophthalmology. Regarding the correct indication for screening for diabetic retinopathy, more physicians who had received their degree less than 5 years previously implemented this practice (54.8%), as opposed to those who had received their MD 20 years or more ago (22.6%). Regarding their experience in funduscopy during their specialty training, 52.4% claimed to have experience, but only 21.4% of those interviewed performed this examination on their patients. According to 84.5% of the interviewees, the fundus examination influenced their clinical treatment program. CONCLUSION: Our study demonstrates that medical knowledge among medical practitioners and endocrinologists on preventive measures and periodicity of diabetic retinopathy examinations appears to be far from ideal for diabetes type 1, but satisfactory for diabetes type 2. Therefore, refresher courses emphasizing the correct management of diabetic patients are necessary, because the social and economic impact of retinopathy is significant.
report on the efficacy and tolerability of Truxima and its cost saving benefit. Aims: This is a multi-centre study to evaluate the safety and overall response rate of Truxima in combination with chemotherapy in patient with an underlying haematological malignancy Methods: This is a local study conducted in London North West Hospital from 1 st of October 2017 to 1 st of April 2018 on patients who received Truxima with or without chemotherapy for B cell malignancy Results: There were 42 patients who received Truxima and 57% (24 out of 42) had a diagnosis of Diffuse Large B Cell Lymphoma (DLBCL). Truxima were generally well tolerated and 90% (38 out of 42) complication the infusion without any complications. There were three patients (7%) who experienced mild IRR which were all grade 2 or less. Amongst the patients who were diagnosed with Diffuse Large B Cell Lymphoma 33% (7 out of 21) achieved complete remission Summary/Conclusion: There were no specific concerns with Truxima as it has shown clinical similarity to MabThera in terms efficacy and safety. Truxima is 10% cheaper per 100 mg in comparison to Mabthera (£314.33 Vs £349.25), therefore it has the advantage of significant budget savings. In the current economic climate, these savings can have a significant impact on health gains at both patient and societal levels.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.